Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma

被引：0
|
作者：
Kim, Byung-Gyu
Choi, Sung Hee
Huong Nguyen
Liang, Fu-Sen
Kim, Seong-Jin
Letterio, John
Huang, Alex
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4554
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ALK-inhibitors as a novel potential therapy for proteasome inhibitor-resistant multiple myeloma
    Besse, Lenka
    Besse, Andrej
    Kraus, Marianne
    Jasik, Matej
    Slaby, Ondrej
    Driessen, Christoph
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
    Staci L. Haney
    Michelle L. Varney
    Jacob T. Williams
    Lynette M. Smith
    Geoffrey Talmon
    Sarah A. Holstein
    Experimental Hematology & Oncology, 11
  • [3] Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
    Haney, Staci L.
    Varney, Michelle L.
    Williams, Jacob T.
    Smith, Lynette M.
    Talmon, Geoffrey
    Holstein, Sarah A.
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [4] Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma
    Haney, Staci L.
    Varney, Michelle L.
    Smith, Lynette M.
    Holstein, Sarah A.
    BLOOD, 2019, 134
  • [5] Combination therapy for treating drug-resistant multiple myeloma
    Kim, Byung-Gyu
    Choi, Sung Hee
    Luo, George
    Kim, Seong-Jin
    Malek, Ehsan
    Driscoll, James
    Letterio, John
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [6] Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
    Bennett, Melissa K.
    Li, Manjun
    Tea, Melinda N.
    Pitman, Melissa R.
    Toubia, John
    Wang, Paul P-S
    Anderson, Dovile
    Creek, Darren J.
    Orlowski, Robert Z.
    Gliddon, Briony L.
    Powell, Jason A.
    Wallington-Beddoe, Craig T.
    Pitson, Stuart M.
    NEOPLASIA, 2022, 24 (01): : 1 - 11
  • [7] Proteasome inhibitor therapy in multiple myeloma
    Chauhan, D
    Hideshima, T
    Mitsiades, C
    Richardson, P
    Anderson, KC
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (04) : 686 - 692
  • [8] Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate
    Bruennert, Daniela
    Seupel, Raina
    Goyal, Pankaj
    Bach, Matthias
    Schraud, Heike
    Kirner, Stefanie
    Koester, Eva
    Feineis, Doris
    Bargou, Ralf C.
    Schlosser, Andreas
    Bringmann, Gerhard
    Chatterjee, Manik
    PHARMACEUTICALS, 2023, 16 (08)
  • [9] High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma
    Stessman, H. A. F.
    Lulla, A.
    Xia, T.
    Mitra, A.
    Harding, T.
    Mansoor, A.
    Myers, C. L.
    Van Ness, B. G.
    Dolloff, N. G.
    LEUKEMIA, 2014, 28 (11) : 2263 - 2267
  • [10] A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis
    Besse, Lenka
    Besse, Andrej
    Mendez-Lopez, Max
    Vasickova, Katerina
    Sedlackova, Miroslava
    Vanhara, Petr
    Kraus, Marianne
    Bader, Jurgen
    Ferreira, Renan B.
    Castellano, Ronald K.
    Law, Brian K.
    Driessen, Christoph
    HAEMATOLOGICA, 2019, 104 (09)
12345